Humacyte initiated with an Overweight at Barclays

Barclays analyst Matt Miksic initiated coverage of Humacyte (HUMA) with an Overweight rating and $3.50 price target The company is in the early stages of launching Symvess in vascular trauma, which is the first of four initial indications for its acellular tissue engineered vessel, the analyst tells investors in a research note. Barclays says the initial indication addresses significant challenges and costs associated with the care of patients suffering from vascular trauma. It sees potential sales of over $600M.